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BREAST CANCER AND FERTILITY
Attitudes on fertility issues in breast cancer patients: an Italian survey
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Abstract
Background: Fertility issues should be discussed with young women before the start of any
anticancer treatment. The study is aimed to investigate the attitude on fertility among Italian
oncologists and breast surgeons dealing with BCa, and to report the consensus achieved on
specific statements.
Methods: One hundred and sixty-two panelists anonymously expressed an opinion through a
web-based platform on 19 statements based on the Delphi method.
Results: Ninety-one percent of oncologists considered important to discuss with patients about
fertility issues and 83% believed estrogens could stimulate the growth of hidden cancer cells in
ER+ tumors. Difficulties in accessing fertility preservation procedures were mainly due to
patients’ reluctance, but also to lack of coordination with the assisted reproduction specialists.
No full consensus was reached on the prognostic role of pregnancy after BCa. Fifty-four percent
of oncologists declared that pregnancy does not affect oncologic prognosis. Treatment with
GnRHa during chemotherapy was considered the only mean for preserving ovarian function.
Conclusions: Fertility preservation in BCa patients is a well-accepted practice among Italian
oncologists. A poor knowledge of this specific issue emerged from the survey, even if a certain
degree of agreement was observed on most fertility-related issues.
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Introduction
Breast cancer (BCa) is the most common malignant tumor in
women, with 48 000 new cases diagnosed in Italy during 2013
[1]. Survival has been steadily increasing in the last 15 years, with
a current 5-year survival of 87%. In 2006, 522 235 women were
living in Italy after diagnosis of BCa, representing almost 1% of
the whole population [1].
Around 6% of BCa cases occur in women540 years [2]. These
patients face specific issues compared to older women, including
an increased risk of recurrence, lower survival and the need of a
broader psychosocial support [3]. Issues related to the effects of
local and systemic treatments such as the alteration of body
image, sexuality complaints and fertility impairment have a higher
priority in this young women population [3].
A recently published EUSOMA recommendation states that
fertility issues must be discussed before the start of any anticancer
treatment and that the optimal technique of fertility preservation,
endocrine treatment duration and the effect of subsequent
pregnancies on BCa prognosis remain research priorities [4].
Oncologists dealing with BCa may have different attitudes
regarding fertility issues in young BCa patients, and few studies
have addressed these topics.
The aim of this article is to present results of an online survey
conducted through the Delphi technique among Italian oncolo-
gists dealing with BCa. Authors developed 19 statements on
fertility issues and fertility preservation techniques in young BCa
patients and agreement or disagreement on each specific state-
ment is reported.
Material and methods
Delphi technique
The essence of Delphi consensus method is to derive quantitative
estimates through qualitative assessment of evidence. The tech-
nique consists of a series of sequential statements administered to
an expert panel to obtain the most reliable consensus. It is an
anonymous structured approach, in which information is gathered
through a number of rounds. Experts’ estimates are aggregated
and fed back anonymously to all participants, who then review
their initial responses in view of group-wide choices. This
practice confers anonymity and allows opinions to be expressed
free from peer group pressure. Usually, this technique is used in
situations where individual opinions and knowledge are selected,
compared and combined in order to address a lack of agreement
or a partial knowledge. The Delphi method was applied in
accordance with reported literature [5–7].
Referee Opinion Leader group
On the basis of a systematic review of literature about BCa and
fertility issues, a national referee group was invited to define the
content of the Delphi statements (two rounds) and to supervise
*These authors contributed equally to this work.
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and comment the whole process. This group consisted of one
gynecologist and two medical oncologists with specific compe-
tences in treating young BCa patients and involved in fertility
preservation techniques. As members of the referee group, they
could not take part into the survey.
Expert panel
Heterogeneity within the expert panel is an important quality
criterion. Therefore, oncologists who strictly collaborated with
breast surgeons on this specific topic were selected. Furthermore,
panelists were representative of all Italian regions, in order to
obtain a better picture of the whole national territory (Figure 1).
Three hundred and forty and 181 experts for the first and the
second round, respectively, were invited to provide their opinion
on different issues: reproductive and endocrine aspects of fertility
preservation techniques, treatment in fertility preservation, preg-
nancy and breastfeeding.
The Delphi process
A multi-round process was created by a web platform and was
started on October 2011 with the first list of 12 statements. Each
statement was formatted allowing to express a different level of
consensus (1¼ strong disagreement, 2¼moderate disagreement,
3¼ agreement with high reservation, 4¼ agreement with minor
reservation and 5¼ strong agreement). A disagreement consensus
was declared when 66% of answers where 1 + 2, while an
agreement consensus was declared when 66% of answer where
3 + 4 + 5.
In accordance with the Delphi methodology, after a first list of
statements, a second list was generated in order to better clarify
some aspects of the questionnaire. A total of 181 participants
completed a first statements-list. The second round of statements
was sent only to those specialists who actively participated in the
first step and was put into the web-based platform on December
2011. The overall Delphi process is represented in Figure 2.
The complete statement list is reported in Tables 1–3.
Results
After proposing the questionnaire to a panel of experts in two
rounds, the percentage of adhesion of the first phase was 53%,
while the second phase showed 90% adhesion. Approximately
91% of responders considered important to discuss fertility issues
and 93% of them stated that they approached this topic even when
the patient did not introduce it. More than 60% of panelists
referred patients to a team of fertility experts for a targeted
counseling (Statement 1).
When answering questions about the most used fertility
preservation techniques, 86% of panelists favored the concomitant
administration of GnRHa and chemotherapy and 78% of them
believed that analogs do not interact with chemotherapy
(Statement 2 and 2a).
Figure 2. Overview of the Delphi procedures
(squares¼ process steps; rhomboids¼ deci-
sion steps).
Figure 1. Expert geographic locations
(second round expert panel step: N¼ 162).
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More than 80% of panelists were not in favor of ovarian
stimulation and embryo cryopreservation procedures. No clear
position was observed on cryopreservation of ovarian tissue
(Statement 2). Conflicting opinions were expressed on the ovarian
stimulation with gonadotropins to obtain mature oocytes: 37% of
oncologists feared a delay in starting chemotherapy and 80%
believed that stimulation could be detrimental in both ER+ and
ER patients. Sixty-five percent of oncologist believed that high
estrogen levels during stimulation could impair the prognosis of
ER+ patients and 83% feared that estrogens could stimulate the
growth of hidden ER+ cancer cells. Thirty-three percent of
panelists showed the same reluctance also in ER patients. Sixty
percent of panelists believed that ovarian stimulation should be
performed only with modified protocols that limit circulating
estrogen levels (Statement 3, 3a and 3b).
More than 80% of panel members were confident that a
successful pregnancy could be obtained after BCa treatment with
the support of fertility preservation techniques, but 50% of them
deemed these techniques still experimental (Statement 4).
A strong patients’ related drawback was pointed out: 65% of
oncologists claimed that women were reluctant to talk with their
physician about fertility and desire for motherhood. Eighty-seven
percent of the panelists thought that scanty information was given
to patients. According to 74% of panelists, this was due to
patient’s young age, low level of education or marital status.
Oncologists’ attitude and knowledge are far from optimal as
well: 93% of them acknowledged having poor insight into the
subject; 64% were reluctant to prescribe any treatment involving
hormonal stimulation and 90% underscored a lack of coordination
between cancer centers and centers for medically assisted
reproduction (Statement 5 and 5a).
A general consensus was obtained among panelists about most
issues relating to the choice of adjuvant systemic therapy in
women who desire to preserve their fertility (Statement 6).
As for chemotherapy, 66% of panelists did not contemplate to
choose a different regimen, just to reduce ovarian toxicity. In
particular, 68% of panelists did not omit alkylating agents and
83% would not consider shorter regimens. A definite consensus
Table 1. Endocrine and reproductive aspects and procedures to preserve fertility.
Statement Options
1. The diagnosis of BCa in young women has become more
frequent. In my opinion, is it important to discuss about
endocrine and reproductive aspects of adjuvant therapies?
 No
 Yes, I discuss these aspects, even if patient don’t ask me about
 Yes, I discuss these aspects, only when patient ask me about
 I invite my patients to contact an expert team
2. In clinical practice, what are the feasible therapeutic options to
preserve fertility in young women with BCa?
 Cryopreservation of ovarian tissue
 Ovarian stimulation and oocyte cryopreservation
 Ovarian stimulation and embryo cryopreservation
 GnRHa in association with chemotherapy
 Association of ovarian stimulation and oocyte/embryo cryo-
preservation with GnRHa adjuvant therapy
2a. About the use of medically assisted reproduction program
(oocyte, embryo and ovarian tissue cryopreservation) to
preserve the fertility in young women affected by BCa:
 In my hospital there is a network/collaboration with a specialized
center for medically assisted reproduction
 I agree to propose the ovarian stimulation
 I’m confident about the real possibility to obtain a pregnancy
3. When could the ovarian stimulation with gonadotropin be
performed to retrieve mature oocytes?
 In all patients with ER+ BCa
 Only in patients with ER BCa
 Only choosing ovarian stimulation protocols that avoid an
estrogenic peak
 Never, because the ovarian stimulation delays the start of
chemotherapy
 It is not relevant because its use is limited
3a. In my clinical practice, I consider feasible the ovarian
stimulation to retrieve mature oocytes in patients with ER+
BCa because
 The ovarian stimulation doesn’t influence the prognosis
 Protocols that limit the estrogenic peak are currently available
 A delay in starting chemotherapy is not relevant
3b. In my clinical practice, I consider feasible the ovarian
stimulation to retrieve oocytes in patients with ER BCa
because
 The ovarian stimulation doesn’t influence the prognosis
 Protocols that limit the estrogenic peak are currently available
 A delay in starting chemotherapy is not relevant
4. In the fertility preservation procedures in patients with BCa, I’m
worried about the following disadvantages:
 Estrogen can promote cellular growth of hidden ER+ cancer cells
 It is possible a negative interaction between chemotherapy and
GnRHa treatment
 I don’t consider important this observation for the final prognosis
 The cost of medically assisted reproduction program
 The experimental nature of medically assisted reproduction
procedures
5. Which are the factors preventing the access to fertility
preservation procedures?
 Few information about these procedures
 Lack of coordination between the oncologic center and the
medically assisted reproduction center
 Complexity for patients to talk about this problem with the
oncologist
 Disturbance factors such as age, instruction, social status, etc.
 Resistance of the oncologist to any type of therapy, that can Induce
hormonal stimulation
5a. Which are the factors preventing the access to ovarian
stimulation?
 Lack of knowledge about this problem in patients
 Worry of patients about the hormonal stimulation required by
medically assisted reproduction protocols
 Lack of knowledge about this problem among oncologists
460 N. Biglia et al. Gynecol Endocrinol, 2015; 31(6): 458–464
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Table 2. The fertility preservation treatment.
Statement Options
6. When I choose the systemic adjuvant treatment in women with BCa
and wishing a pregnancy, do I module the treatment and choose
medications in order to preserve also the fertility?
 Never
 I choose a treatment with reduced ovarian toxicity
 I reduce the duration of tamoxifen therapy
 I don’t use tamoxifen also in patients with ER+ BCa
6a. In my clinical practice, do I module the systemic adjuvant therapy
in order to preserve the fertility in women with BCa?
 I choose a chemotherapeutic treatment without alkylating agents
 I reduce the duration of chemotherapy
 I use a standard chemotherapeutic protocol in association with
GnRHa treatment in patients with ER+ BCa
 I use a standard chemotherapeutic protocol in association with
GnRHa treatment in patients with ER BCa
7. Recent meta-analysis studies indicate that the combination of
chemotherapy with GnRHa treatment also in patients with ER
BCa reduces the risk of permanent amenorrhea in comparison to
chemotherapy alone
 I never consider this option
 I don’t think this could be efficient
 I usually use this option in young patients (also ER) candidated for
chemotherapy
 Literature data are not conclusive
 I’m not informed and I would like to update
7a. The results from the Cochrane Reviews and the PROMISE study
support the notion that the concomitant use of GnRHa treatment
and chemotherapy is efficient to reduce the risk of permanent
amenorrhea in young patients
 Up to date, data from literature are not conclusive
 I will consider this option for young women candidate to
chemotherapy
 I already use this option to preserve the ovarian function
8. Could a young woman be affected by precocious menopause after
adjuvant therapy for BCa?
 I think that this consequence is ineluctable and of little relevance
 I show her non-hormonal alternatives for menopausal
symptoms
 I think that this could be positive, especially for hormone sensitive
carcinomas
 I choose a treatment with reduced ovarian toxicity
9. My attitude toward the combination of GnRHa with tamoxifen
treatment in patients with ER+ BCa is
 I don’t propose the combination
 I propose the combination for 2 years
 I propose the combination for 2 years, eventually prolonged for
5 years
 I propose the combination for 5 years
 I prescribe the tamoxifen treatment for 5 years and GnRHa until
menopause
9a. I choose to prolong the GnRHa treatment for 5 years in
combination with tamoxifen
 In young women (35–40 years old)
 In women with high risk of recurrence
 In women near to physiologic menopause
 In absence of pathologies related with precocious menopause
(osteoporosis, vaginal dryness)
Table 3. Pregnancy and breastfeeding.
Statement Options
10. May a pregnancy in women previously affected by BCa
increase the risk of recurrence?
 Yes, because the elevated circulating estrogen levels during pregnancy
may induce cellular growth in hidden cancer cells
 Yes, but only if pregnancy occurs within 2 years after surgical
intervention
 No, it doesn’t influence the prognosis
 No, the pregnancy is not dangerous for the mother, but it presents an
increased incidence of malformation and abortion as a consequence of
pharmacologic treatments previously used
11. In young women affected by mutated BRCA BCa and
wishing pregnancy
 I discourage any ovarian stimulation procedure to retrieve oocytes
 I discourage the cryopreservation of ovarian tissue for the high risk of
ovarian carcinoma in this population
 I don’t see any counter indication
 I discourage the pregnancy because of the risk to transmit the mutated
gene to babies
12. To a patient previously affected by BCa that wishes to
breastfeed
 I discourage to breastfeed because it is contraindicated after chemother-
apy
 I explain that it is possible the unilateral breast-feeding
 I explain that it is not necessary because bottle-feeding is equivalent to
breast-feeding
 I support as I can this desire
DOI: 10.3109/09513590.2014.1003293 Fertility preservation cancer 461
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was obtained also for endocrine therapy: 94% of panelists did not
omit tamoxifen and 76% did not shorten tamoxifen duration
(Statement 6 and 6a).
Eighty-six percent and 72% of panelists considered the
administration of GnRHa during chemotherapy as the only
medical strategy available for preserving ovarian function inde-
pendently of the expression of hormone receptors (Statement 6a).
No definite consensus, however, was obtained on the con-
comitant administration of GnRHa and chemotherapy in their
common clinical practice, although 65% of panelists declared to
use it regularly. On the other hand, according to 43% of panelists,
scientific evidence about this is not convincing (Statement 7).
When panelists were made aware of the PROMISE study [8] and
the Cochrane Review [9] results, 90% of them admitted that
scientific data were solid enough and the proportion of panelists
declaring to regularly use GnRHa in clinical practice rose up to
79%, while 92% would consider to use it (Statement 7a).
As for the safety and feasibility of pregnancy after BCa,
conflicting opinions emerged from panelists, without achieving a
consensus. Only 54% of oncologists believed that pregnancy does
not affect the prognosis of BCa patients, while 49% of them
supports that an increase in estrogen levels during pregnancy could
stimulate the growth of hidden tumor cells (Statement 10).
However, 40% of them expressed that the increased risk of relapse
occurs only when pregnancy comes in the first 2 years after
diagnosis. Most panelists (60%) disagreed with the statement that a
higher percentage of fetal malformations is present in pregnancies
occurring after BCa (Statement 10). Many panelists (56 and 57%,
respectively) agreed on avoiding hormonal stimulation or cryo-
preservation of ovarian tissue in BRCA positive BCa patients.
Although consensus was not achieved, 56% of panelists stated
that pregnancy in BRCA patients could be harmful, but 62% did
not believe that pregnancy should be avoided for the risk of
inherited mutated gene (Statement 11).
A full consensus was reached on statements related to
breastfeeding after BCa. Most panelists (91%) believed that,
when a woman desires to breastfeed her baby, she should be
encouraged to do so and supported, and 70% of them regularly
informed their patients that unilateral breastfeeding is possible.
Only 16% of oncologists discouraged maternal breastfeeding and
46% believed that breastfeeding is not necessary due to the
equivalence with bottle feeding (Statement 12).
Discussion
We have used the Delphi method to investigate the attitudes on
fertility issues among Italian oncologists and breast surgeons and
to report the consensus achieved on specific statements. This
method is anonymous and doesn’t allow any discussion or
possible direct contact between panellists and referees who
analyze and comment on the survey results without interfering
with responses and attitudes. The first and second rounds of the
survey have a different number of participants because the second
list of question was sent only to panellists who participated in the
first round.
From our interviews to a representative panel of Italian
oncologists expert in BCa treatment, it was clear that they
consistently declare their interest in fertility preservation in BCa
patients. There was a strong consensus in considering relevant the
discussion with patients on fertility preservation issues and in
dealing with this topic even when women were not mentioning it.
Inconsistent opinions emerged about specific fertility preser-
vation strategies. Currently, fertility preservation techniques rely
on cryopreservation of embryos, cryopreservation of mature
oocytes, cryopreservation of ovarian tissue and the concomitant
administration of GnRHa and chemotherapy [10]. The first three
techniques are part of a medically assisted reproduction programs
and require patient’s referral to a specialized center. Each of these
techniques shows advantages and disadvantages that must be
evaluated considering each single case, but all of them must be
started before oncologic treatments.
Embryo cryopreservation is a well-established technique but in
Italy this procedure is forbidden by the law [11]. Oocyte
cryopreservation requires ovarian stimulation, mature oocyte
retrieval and subsequent freezing or vitrification. Thawing and
intracytoplasmic sperm injection (ICSI) with embryo transfer can
be performed years after the procedure. The reluctance to accept
ovarian stimulation and oocyte cryopreservation derives from the
fear that this procedure might delay the beginning of adjuvant
therapy and that the high estrogen levels during the stimulation
could promote the growth of hidden cancer cells. The delay is not
a major issue because ovarian stimulation takes 2 weeks and
several studies show no difference in terms of survival or
recurrence, if chemotherapy is started within 12 weeks after
surgery [12]. A further controversy concerning ovarian stimula-
tion is the use of gonadotrophins in ER+ and in ER patients.
Panelists agreed that ovarian stimulation does not influence the
prognosis in ER- patients, while 65% of panelists believe that it
could worsen the prognosis of ER+ patients since estrogens may
promote the growth of occult ER+ cancer cells. The levels of
serum estradiol (E2) during ovarian stimulation can be 20 times
higher than in a natural menstrual cycle. Some authors believe
that there is no real risk in having a short-term increase in
hormones levels, if chemotherapy is administered shortly after
[13]. Recently, ovarian stimulation protocols with aromatase
inhibitors have been proposed to avoid high estradiol levels and
the recurrence rate of BCa does not seem to be increased [14,15].
Due to the short-term follow-up and the small number of patients,
a final statement on the safety of this approach cannot be issued
yet. Azim et al. [16] suggest that the use of letrozole and
gonadotrophins for controlled ovarian stimulation was unlikely to
result in a significant increase in recurrence of BCa. Further
research, including longer term follow-ups, is needed to confirm
these findings; in the meantime, the use of letrozole-FSH protocol
in women with BCa who wish to preserve their fertility by oocyte
or embryo cryopreservation is certainly an option [16]. In fact,
ovarian stimulation protocols that determine a limited increase in
estrogen levels are accepted by the vast majority of panelists.
Ovarian tissue cryopreservation is still an experimental
technique but in recent years has achieved interesting results.
Ovarian tissue sampling can be carried out at any time of
menstrual cycle, without delay in starting therapies, and it may be
performed laparoscopically. At an appropriate time, when the
patient decides to attempt pregnancy, the orthotopical transplant-
ation has the greatest chances of success [17]. This technique does
not require hormonal stimulation and allows the storage of a very
large number of follicles.
In our survey, the lack of confidence in the cryopreservation of
ovarian tissue derives from the experimental nature of the
technique and the small number of pregnancies reported in
literature. To date,430 children have been born worldwide after
ovarian tissue cryopreservation [1] and the first live birth in Italy
has been reported in February 2012 [18].
Finally, other difficulties emerged from our survey about
fertility preservation in Italy. Patients are reluctant to talk about
their fertility and desire for motherhood with their doctor.
Moreover, they are poorly informed and fear that hormonal
stimulation may be harmful to their health. Physicians admit a
lack of knowledge on these issues as well. More than 50% of
panelists were against any hormonal stimulation and 90% of them
underscored a lack of coordination between cancer centers and
centers for medically assisted reproduction.
462 N. Biglia et al. Gynecol Endocrinol, 2015; 31(6): 458–464
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Should the desire of fertility preservation affect the choice of
adjuvant systemic therapy? According to panelists participating in
this survey, no change in indications both for chemotherapy and
endocrine therapy should be taken into account in young patients
who plan future pregnancies. In particular, oncologists would not
omit alkylating agents and would not shorten the duration of
chemotherapy to decrease the risk of ovarian impairment. Also, a
sharp consensus was obtained on the modulation of endocrine
therapy.
Endocrine therapies do not directly affect ovarian reserve
except for the aging of ovaries during treatment. Virtually no
oncologist would omit tamoxifen and about three out of four
would not shorten the duration of treatment. Indeed, the recently
updated results of the ABCSG12 study showed a 5-year disease-
free interval of 90% in women receiving the combination of
GnRHa + tamoxifen for 3 years [19].
GnRHa have been consistently considered the only medical
tool to preserve fertility during the administration of adjuvant
chemotherapy. A high proportion of oncologists would prescribe
concurrent GnRHa and chemotherapy in both ER+ and ER
tumors. On the other hand, mixed opinions were expressed by
panelists on the soundness of available scientific evidence on the
role of GnRHa in the preservation of ovarian reserve. After the
first interview 65% of panelists declared they routinely co-
prescribe GnRHa and chemotherapy. Nonetheless, about half of
them declared that the scientific evidence was not convincing and
a similar proportion expressed the need for further information.
These opinions reflect the ongoing uncertainty about this issue.
Despite the increasing amount of published data, an international
consensus on the gonadoprotective role of GnRHa has not been
reached and ovarian suppression with GnRHa during chemother-
apy as a method to preserve fertility remains a highly controver-
sial topic. The very recently updated clinical practice guidelines
for fertility preservation in cancer patients released by ASCO in
2013 conclude that, given the current status of knowledge on this
issue, GnRHa is not an effective method for fertility preservation
and encourage the inclusion of patients in clinical studies [20].
ESMO recommendations on cancer, pregnancy and fertility draw
similar conclusions [21]. The large differences among studies in
the definition of amenorrhea and the lack of standardized and
reliable markers of residual ovarian reserve contribute to keep this
debate open. A recent Cochrain review including only rando-
mized clinical trials showed a positive effect of GnRHa admin-
istration on the likelihood of resuming menses [relative risk (RR)
1.90; 95% confidence interval (CI) 1.30–2.79] and concluded that
GnRHa should be given before or during chemotherapy in
reproductive age women, although no significant difference in
pregnancy rates was observed [9]. In the largest published
randomized study (PROMISE) which included 300 patients,
9% of patients in the GnRHa arm resumed menses or showed
FSH levels in the premenopausal range after 1 year versus 26% in
the arm treated with chemotherapy alone [8]. On the other hand,
the ZORO study failed to show any protective effect of the
concurrent administration of goserelin on the rate of amenorrhea
at 6 months, anyhow the sample size was much smaller than in the
other studies [22]. These studies were provided to the panelists
before the second round, as a result, the proportion of panelists
who acknowledged that scientific evidence was sound enough
rose from 43 to 90%, with 490% declaring that they would
consider prescribing GnRH analogs in their clinical practice.
Controversies and different opinions were expressed by
panelists on the safety of pregnancy after BCa without reaching
consensus. Many of them (54 and 49%) do not feel confident in
suggesting pregnancy in BCa patients as they believe that it could
promote hidden cancer cells growth and impair prognosis. Many
studies have shown that pregnancy does not affect prognosis, both
in ER+ and ER patients, some even suggest a protective effect of
pregnancy [23]. In 2010, a large meta-analysis was published by
Azim et al. [24], with data from 14 studies for a total number of
1244 cases and 18 145 controls. Authors showed a better overall
survival in women who got pregnant following BCa diagnosis
compared to those who did not get pregnant [hazard ratio (HR)
0.59; 95% CI 0.50–0.70] [24]. Authors hypothesized that these
results could be weakened by a selection bias, known as the
‘‘healthy mother effect’’ phenomenon, but also the sensitivity
analysis, performed including only those studies that had BCa
controls known to be relapse-free, showed a trend toward
improved survival in women who got pregnant (HR 0.85; 95%
CI 0.53–1.35) [24]. Consistent results were described by Kranick
et al. [25] in the same period.
Recently, this evidence has been confirmed by Azim et al. [26]
in another large multicenter study, evaluating the prognostic
impact of pregnancy in a subgroup of women with a previous ER+
BCa. A total of 1207 patients were included in the study, 333
women who became pregnant after BCa and 874 controls, who
did not became pregnant [27]. No difference in overall event rate
was observed between cases and controls (HR 0.84; 95% CI 0.66–
1.06; p¼ 0.14). Of note, no difference was observed in either ER+
or ER cohorts. Better overall survival rates were reported in the
pregnant patients group (p¼ 0.03), independent of ER status
(p¼ 0.11). Moreover, in this study breastfeeding and time to
pregnancy seemed to have no effect on risk of relapse in women
who achieved a term pregnancy [26]. Studies that analyzed the
effect of pregnancy in BRCA positive BCa patients came to the
same conclusions: pregnancy seems to have a favorable effect on
prognosis in BRCA positive population as well [27,28]. Italian
oncologists agreed on the importance of breastfeeding in BCa
patients who underwent surgery, and on the need to counsel
patients about it. Advantages of breastfeeding on babies’ health
are undisputed but many studies have shown also the positive role
of breastfeeding on BCa patients outcome [29,30]. After surgery
and radiotherapy the treated breast is usually hypotrophic,
produces less or no milk and therefore, it is not possible to
breastfeed from it. Unilateral breastfeeding should be encouraged
and supported in BCa patients because it is frequently enough for
baby’s growth. Great importance should be given to breastfeeding
counseling and to supporting patients, since misinformation is the
main cause for avoiding breastfeeding [31].
Conclusions
Recently published clinical practice guidelines update by ASCO,
reviews 4200 new publications from 2006 to 2012 reporting
studies results on fertility intervention in cancer patients [20].
This large number of publications underscores the extreme
relevance gained by this topic and supports the guidelines
recommendation to offer to all young patients a fertility counsel-
ing before starting any antineoplastic treatment.
Our survey, administered to a large panel of experts dealing
with BCa, confirms that Italian health care providers are aware of
this issue but points out they have a limited knowledge on several
aspects of it and underscores the practical difficulties oncologists
meet when considering referring a patient to a fertility center.
Young patients must not be undertreated when expressing a desire
of pregnancy, physicians should share with them the updated
evidence on the feasibility and safety of pregnancy after cancer
and the available options for fertility preservation in order to take
a thoroughly informed decision.
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